|
UTP14C expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
6.72069999652081E-08 |
| Normal-vs-Stage3 |
1.99840144432528E-15 |
| Normal-vs-Stage4 |
3.33066907387547E-16 |
| Stage1-vs-Stage2 |
3.361600E-01 |
| Stage1-vs-Stage3 |
2.139600E-02 |
| Stage1-vs-Stage4 |
1.756310E-03 |
| Stage2-vs-Stage3 |
3.217900E-02 |
| Stage2-vs-Stage4 |
6.203900E-03 |
| Stage3-vs-Stage4 |
3.251400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.0406999999546E-06 |
| Normal-vs-Asian |
6.31961150077132E-12 |
| Caucasian-vs-AfricanAmerican |
2.921800E-01 |
| Caucasian-vs-Asian |
8.387400E-01 |
| AfricanAmerican-vs-Asian |
2.822400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62458935193399E-12 |
| Male-vs-Female |
3.776200E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62525548574877E-12 |
| Normal-vs-Age(41-60Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(61-80Yrs) |
1.6547874182038E-12 |
| Normal-vs-Age(81-100Yrs) |
1.368030E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.089000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.788390E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.141200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.269600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.327400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.584800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.798700E-04 |
| Classical-VS-Follicular |
4.227800E-01 |
| Classical-VS-Other |
1.035020E-01 |
| Classical-VS-Normal |
1.35225164399344E-12 |
| Tall-VS-Follicular |
1.236950E-03 |
| Tall-VS-Other |
6.384400E-01 |
| Tall-VS-Normal |
8.88178419700125E-16 |
| Follicular-VS-Other |
1.208190E-01 |
| Follicular-VS-Normal |
2.95680036010992E-10 |
| Other-VS-Normal |
1.81342999999723E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
3.10862446895044E-15 |
| N0-vs-N1 |
2.856100E-02 |
|
|
